Jennings Jessica Amber, Carpenter Daniel P, Troxel Karen S, Beenken Karen E, Smeltzer Mark S, Courtney Harry S, Haggard Warren O
Department of Biomedical Engineering, University of Memphis, 330 Engineering Technical Building, Memphis, TN, 38152-3210, USA,
Clin Orthop Relat Res. 2015 Jul;473(7):2270-82. doi: 10.1007/s11999-014-4130-8.
Orthopaedic biomaterials are susceptible to biofilm formation. A novel lipid-based material has been developed that may be loaded with antibiotics and applied as an implant coating at point of care. However, this material has not been evaluated for antibiotic elution, biofilm inhibition, or in vivo efficacy.
QUESTIONS/PURPOSES: (1) Do antibiotic-loaded coatings inhibit biofilm formation? (2) Is the coating effective in preventing biofilm in vivo?
Purified phosphatidylcholine was mixed with 25% amikacin or vancomycin or a combination of 12.5% of both. A 7-day elution study for coated titanium and stainless steel coupons was followed by turbidity and zone of inhibition assays against Staphylococcus aureus and Pseudomonas aeruginosa. Coupons were inoculated with bacteria and incubated 24 hours (N = 4 for each test group). Microscopic images of biofilm were obtained. After washing and vortexing, attached bacteria were counted. A mouse biofilm model was modified to include coated and uncoated stainless steel wires inserted into the lumens of catheters inoculated with a mixture of S aureus or P aeruginosa. Colony-forming unit counts (N = 10) and scanning electron microscopy imaging of implants were used to determine antimicrobial activity.
Active antibiotics with colony inhibition effects were eluted for up to 6 days. Antibiotic-loaded coatings inhibited biofilm formation on in vitro coupons (log-fold reductions of 4.3 ± 0.4 in S aureus and 3.1 ± 0 for P aeruginosa in phosphatidylcholine-only coatings, 5.6 ± 0 for S aureus and 3.1 ± 0 for P aeruginosa for combination-loaded coatings, 5.5 ± 0.3 for S aureus in vancomycin-loaded coatings, and 3.1 ± 0 for P aeruginosa for amikacin-loaded coatings (p < 0.001 for all comparisons of antibiotic-loaded coatings against uncoated controls for both bacterial strains, p < 0.001 for comparison of antibiotic-loaded coatings against phosphatidylcholine only for S aureus, p = 0.54 for comparison of vancomycin versus combination coating in S aureus, P = 0.99 for comparison of antibiotic- and unloaded phosphatidylcholine coatings in P aeruginosa). Similarly, antibiotic-loaded coatings reduced attachment of bacteria to wires in vivo (log-fold reduction of 2.54 ± 0; p < 0.001 for S aureus and 0.83 ± 0.3; p = 0.112 for P aeruginosa).
Coatings deliver active antibiotics locally to inhibit biofilm formation and bacterial growth in vivo. Future evaluations will include orthopaedic preclinical models to confirm therapeutic efficacy.
Clinical applications of local drug delivery coating could reduce the rate of implant-associated infections.
骨科生物材料易形成生物膜。已开发出一种新型脂质基材料,可负载抗生素并在医疗现场用作植入物涂层。然而,这种材料尚未进行抗生素洗脱、生物膜抑制或体内疗效评估。
问题/目的:(1)负载抗生素的涂层是否能抑制生物膜形成?(2)该涂层在体内预防生物膜是否有效?
将纯化的磷脂酰胆碱与25%的阿米卡星或万古霉素或两者各12.5%的组合混合。对涂覆的钛和不锈钢试片进行为期7天的洗脱研究,随后针对金黄色葡萄球菌和铜绿假单胞菌进行浊度和抑菌圈测定。将试片接种细菌并孵育24小时(每个测试组N = 4)。获取生物膜的显微镜图像。洗涤并涡旋后,对附着的细菌进行计数。对小鼠生物膜模型进行改良,使其包括插入接种有金黄色葡萄球菌或铜绿假单胞菌混合物的导管内腔中的涂覆和未涂覆的不锈钢丝。使用菌落形成单位计数(N = 10)和植入物的扫描电子显微镜成像来确定抗菌活性。
具有菌落抑制作用的活性抗生素可洗脱长达6天。负载抗生素的涂层在体外试片上抑制生物膜形成(仅磷脂酰胆碱涂层中金黄色葡萄球菌的对数减少倍数为4.3±0.4,铜绿假单胞菌为3.1±0;组合负载涂层中金黄色葡萄球菌为5.6±0,铜绿假单胞菌为3.1±0;万古霉素负载涂层中金黄色葡萄球菌为5.5±0.3,阿米卡星负载涂层中铜绿假单胞菌为3.1±0(两种菌株的负载抗生素涂层与未涂覆对照的所有比较p < 0.001,金黄色葡萄球菌的负载抗生素涂层与仅磷脂酰胆碱的比较p < 0.001,金黄色葡萄球菌中万古霉素与组合涂层的比较p = 0.54,铜绿假单胞菌中抗生素和未负载磷脂酰胆碱涂层的比较p = 0.99)。同样,负载抗生素的涂层在体内减少了细菌在钢丝上的附着(金黄色葡萄球菌的对数减少倍数为2.54±0;p < 0.001,铜绿假单胞菌为0.83±0.3;p = 0.112)。
涂层可在局部递送活性抗生素以抑制体内生物膜形成和细菌生长。未来的评估将包括骨科临床前模型以确认治疗效果。
局部药物递送涂层的临床应用可降低植入物相关感染的发生率。